Literature DB >> 22925718

Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.

Lei He1, John C Grecula, Yonghua Ling, Michael D Enzerra, Mario Ammirati, Kari Kendra, Robert Cavaliere, Nina Mayr, John McGregor, Thomas Olencki, Ewa Mrozek, Mani Matharbootham, Chima Oluigbo, Mitch A Phelps.   

Abstract

A liquid chromatography-tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue was developed and fully validated. Methanol was used to precipitate proteins in brain tissue. Bendamustine and internal standard (chlorambucil) were separated with reverse-phase chromatography on a C-18 column with a gradient of water and 95% methanol in 0.1% formic acid. Positive mode electrospray ionization was applied with selected reaction monitoring to achieve 5 ng/ml lower limits of quantitation in mouse brain tissue. The calibration curve for bendamustine in mouse brain was linear between 5 and 2000 ng/ml. The within- and between-batch accuracy and precision of the assay were within 15% at 10, 100 and 1000 ng/ml. The recovery and matrix effect of bendamustine in mouse brain tissue ranged from 41.1% to 51.6% and 107.4% to 110.3%, respectively. The validated method was then applied to quantitate bendamustine in an animal study. Results indicate the assay can be applied to evaluate bendamustine disposition in mouse brain tissue. This assay will be applied in the future to detect and quantify bendamustine in human brain tissue samples.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925718      PMCID: PMC3856370          DOI: 10.1016/j.jchromb.2012.08.013

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  24 in total

Review 1.  Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Authors:  E Marleen Kemper; Willem Boogerd; Ingrid Thuis; Jos H Beijnen; Olaf van Tellingen
Journal:  Cancer Treat Rev       Date:  2004-08       Impact factor: 12.111

2.  Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.

Authors:  Joel S Owen; Murad Melhem; Julie A Passarell; Denise D'Andrea; Mona Darwish; Bradley Kahl
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-06       Impact factor: 3.333

Review 3.  Management of brain metastases.

Authors:  Riccardo Soffietti; Roberta Rudā; Roberto Mutani
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

4.  Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma.

Authors:  Jens Teichert; Reinhard Sohr; Frank Baumann; Lothar Hennig; Karlheinz Merkle; Karel Caca; Rainer Preiss
Journal:  Drug Metab Dispos       Date:  2005-04-21       Impact factor: 3.922

5.  Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride.

Authors:  Jens Teichert; Frank Baumann; Qi Chao; Craig Franklin; Brandy Bailey; Lothar Hennig; Karel Caca; Konrad Schoppmeyer; Ulrich Patzak; Rainer Preiss
Journal:  Cancer Chemother Pharmacol       Date:  2006-09-07       Impact factor: 3.333

Review 6.  Bendamustine: a new treatment option for chronic lymphocytic leukemia.

Authors:  Ashley E Glode; Anthony Jarkowski
Journal:  Pharmacotherapy       Date:  2009-11       Impact factor: 4.705

Review 7.  Targeted therapy for brain metastases: improving the therapeutic ratio.

Authors:  Rakesh R Patel; Minesh P Mehta
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

8.  Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride.

Authors:  Jens Teichert; Reinhard Sohr; Lothar Hennig; Frank Baumann; Konrad Schoppmeyer; Ulrich Patzak; Rainer Preiss
Journal:  Drug Metab Dispos       Date:  2008-10-29       Impact factor: 3.922

Review 9.  Bendamustine: a new look at an old drug.

Authors:  Matt Kalaycio
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.

Authors:  M Rasschaert; D Schrijvers; J Van den Brande; J Dyck; J Bosmans; K Merkle; J B Vermorken
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

View more
  2 in total

1.  Determination of Bendamustine in Human Plasma and Urine by LC-FL Methods: Application in a Drug Monitoring.

Authors:  Alina Plenis; Agnieszka Frolow; Natalia Rekowska; Ilona Olędzka; Piotr Kowalski; Ewa Bień; Małgorzata Anna Krawczyk; Elżbieta Adamkiewicz-Drożynska; Tomasz Bączek
Journal:  Chromatographia       Date:  2016-05-18       Impact factor: 2.044

2.  Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

Authors:  Bassam M Ayoub; Shereen Mowaka; Marwa M Safar; Nermeen Ashoush; Mona G Arafa; Haidy E Michel; Mariam M Tadros; Mohamed M Elmazar; Shaker A Mousa
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.